Literature DB >> 31840602

Current Position on the Role of Monomeric C-reactive Protein in Vascular Pathology and Atherothrombosis.

Ivan S Melnikov1,2, Sergey G Kozlov1, Olga S Saburova1, Yulia N Avtaeva1, Lyudmila V Prokofieva1, Zufar A Gabbasov1.   

Abstract

C-reactive Protein (CRP) is an acute phase reactant, belonging to the pentraxin family of proteins. Its level rises up to 1000-fold in response to acute inflammation. High sensitivity CRP level is utilized as an independent biomarker of inflammation and cardiovascular disease. The accumulating data suggests that CRP has two distinct forms. It is predominantly produced in the liver in a native pentameric form (nCRP). At sites of local inflammation and tissue injury it may bind to phosphocholine-rich membranes of activated and apoptotic cells and their microparticles, undergoing irreversible dissociation to five monomeric subunits, termed monomeric CRP (mCRP). Through dissociation, CRP deposits into tissues and acquires distinct proinflammatory properties. It activates both classic and alternative complement pathways, binding complement component C1q and factor H. mCRP actively participates in the development of endothelial dysfunction. It activates leukocytes, inducing cytokine release and monocyte recruitment. It may also play a role in the polarization of monocytes and T cells into proinflammatory phenotypes. It may be involved in low-density lipoproteins (LDL) opsonization and uptake by macrophages. mCRP deposits were detected in samples of atherosclerotic lesions from human aorta, carotid, coronary and femoral arteries. mCRP may also induce platelet aggregation and thrombus formation, thus contributing in multiple ways in the development of atherosclerosis and atherothrombosis. In this mini-review, we will provide an insight into the process of conformational rearrangement of nCRP, leading to dissociation, and describe known effects of mCRP. We will provide a rationalization for mCRP involvement in the development of atherosclerosis and atherothrombosis. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Monomeric C-reactive protein; atherosclerosis; atherothrombosis; complement; dissociation; inflammation; modified C-reactive protein.

Year:  2020        PMID: 31840602     DOI: 10.2174/1381612825666191216144055

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

1.  High-sensitivity C-reactive protein as a better predictor of post-thrombolytic functional outcome in patients with previous antiplatelet therapy.

Authors:  Tan Li; Qiannan Yu; Yiqing Wang; Xiuying Cai; Yan Kong; Hongru Zhao; Shanshan Diao; Yiren Qin; Qi Fang
Journal:  Eur J Med Res       Date:  2022-06-03       Impact factor: 4.981

Review 2.  Diagnoses Based on C-Reactive Protein Point-of-Care Tests.

Authors:  Miroslav Pohanka
Journal:  Biosensors (Basel)       Date:  2022-05-17

Review 3.  Monomeric C-Reactive Protein - A Feature of Inflammatory Disease Associated With Cardiovascular Pathophysiological Complications?

Authors:  Yasmin Zeinolabediny; Shant Kumar; Mark Slevin
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

4.  Potential Therapeutic Anti-Inflammatory and Immunomodulatory Effects of Dihydroflavones, Flavones, and Flavonols.

Authors:  Cristina Zaragozá; Lucinda Villaescusa; Jorge Monserrat; Francisco Zaragozá; Melchor Álvarez-Mon
Journal:  Molecules       Date:  2020-02-24       Impact factor: 4.411

Review 5.  Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches.

Authors:  Yuefei Jin; Wangquan Ji; Haiyan Yang; Shuaiyin Chen; Weiguo Zhang; Guangcai Duan
Journal:  Signal Transduct Target Ther       Date:  2020-12-24

Review 6.  C-Reactive Protein: Friend or Foe? Phylogeny From Heavy Metals to Modified Lipoproteins and SARS-CoV-2.

Authors:  Michael Torzewski
Journal:  Front Cardiovasc Med       Date:  2022-03-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.